Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene

Project MinE ALS Sequencing Consortium

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
16 Downloads (Pure)


Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease. CAV1 and CAV2 organize membrane lipid rafts (MLRs) important for cell signaling and neuronal survival, and overexpression of CAV1 ameliorates ALS phenotypes in vivo. Genome-wide association studies localize a large proportion of ALS risk variants within the non-coding genome, but further characterization has been limited by lack of appropriate tools. By designing and applying a pipeline to identify pathogenic genetic variation within enhancer elements responsible for regulating gene expression, we identify disease-associated variation within CAV1/CAV2 enhancers, which replicate in an independent cohort. Discovered enhancer mutations reduce CAV1/CAV2 expression and disrupt MLRs in patient-derived cells, and CRISPR-Cas9 perturbation proximate to a patient mutation is sufficient to reduce CAV1/CAV2 expression in neurons. Additional enrichment of ALS-associated mutations within CAV1 exons positions CAV1 as an ALS risk gene. We propose CAV1/CAV2 overexpression as a personalized medicine target for ALS.

Original languageEnglish
Article number108456
Number of pages13
JournalCell Reports
Issue number9
Publication statusPublished - 01 Dec 2020
Externally publishedYes

Bibliographical note

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.


Dive into the research topics of 'Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene'. Together they form a unique fingerprint.

Cite this